Objective: The primary aim of the present study was to evaluate the data and success of a smoking cessation clinic in a secondary state hospital. Secondarily, the study aimed to compare the cessation rates of patients using varenicline and bupropion. Methods: A total of 251 patients, admitted to our smoking cessation clinic were retrospectively evaluated. The smoking cessation clinic was run one day every week and included a 35-min presentation on smoking cessation and face-to-face interviews with every patient who attended the clinic. Monthly control visits were conducted, and after 2 years all the patients were asked about their smoking status via a phone call.Results: A total of 152 out of the 251 patients, namely those who were successfully contacted, were included in the study. The average age of the study population was 46.2±11.2 (18-69), and 81 (53.3%) were female. The average nicotine dependence level was 5.8±2.3. The nicotine dependence levels and the amount of current cigarette consumption in one day were higher in the varenicline group (p=0.003 and p=0.002, respectively), whereas the duration of treatment was lower (p=0.009). Among all the patients, the average smoking cessation rate was 61.2% in 6 months, 34.2% in 12 months, 18.4% in 18 months, and 5.3% in 24 months. There were no differences in smoking cessation rates between the varenicline and bupropion groups (p>0.05). Conclusion: An effective success in smoking cessation was observed with the combined use of behavioral and pharmacological modalities. Intensive behavioral interventions and treatment and follow up for longer durations, particularly for patients with risk factors for relapse, can increase the success of smoking cessation clinics
WHO Report on Global Tobacco Epidemic, 2013: enforcing bans on to- bacco advertising, promotion and sponsorship. Available from: URL: http://www.who.int/tobacco/global_report/2013/en/ Accessed No- vember 28, 2014.
Bilir N, Çakır B, Dağlı E, Ergüder T, Önder Z. Tobacco Control in Turkey. WHO Europe, 2009. Available from: URL: http://www.euro.who.int/__data/as- sets/pdf_file/0004/98446/E93038.pdf Accessed November 1, 2014.
WHO Report on Global Tobacco Epidemic, 2008: Mpower package. Available from: URL: http://www.who.int/tobacco/mpower/2008/en/ Accessed November 28, 2014.
Global Adult Tobacco Survey Turkey Report 2008. Ministry of Health, Publication No: 803, Ankara, 2010.
Global Adult Tobacco Survey Turkey Report 2012. Ministry of Health, Publication No: 948, Ankara, 2014.
Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerst- rom Test for Nicotine Dependence: a revision of the Fagerstrom Tole- rance Questionnaire. Br J Addict 1991; 86: 1119-27. [CrossRef]
Rigotti NA. Clinical practice. Treatment of tobacco use and dependen- ce. N Engl J Med 2002; 346: 506-12. [CrossRef]
Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Servi- ces. Public Health Service. May 2008.
Yaşar Z, Kurt ÖK, Talay F, Kargı A. One-year follow up results of smoking cessation outpatient clinic: Factors affecting the cessation of smoking. Eurasian J Pulmonol 2014; 16: 99-104. [CrossRef]
Abakay Ö, Abakay A, Tanrıkulu AÇ, Şen HS, Sezgi C, Dallı A, et al. The outcome of patients that admitted to outpatients of smoking cessati- on. J Chest Dis Crit Care Med 2014; 1: 7-10. [CrossRef]
Argüder E, Karalezli A, Hezer H, Kılıç H, Er M, Hasanoğlu HC, et al. Factors affec- ting the success of smoking cessation. Turk Thorac J 2013; 14: 81-7. [CrossRef]
Sağlam L. Investigation of the results of a smoking cessation clinic and the factors associated with success. Turk J Med Sci 2012; 42: 515-22.
Çan G, Öztuna F, Özlü T. The evaluation of outpatient smoking cessati- on clinic results. Tuberc Thorax 2004; 52: 63-74.
Salepçi B, Fidan A, Oruç Ö, Torun E, Çağlayan B, Kader ŞN. Success rates in our smoking cessation clinic and factors affecting it. Turk Thorac J 2005; 6: 151-8.
Krall EA, Garvey AJ, Garcia RI. Smoking relapse after 2 years of absti- nence: findings from the VA Normative Aging Study. Nicotine Tob Res 2002; 4: 95-100. [CrossRef]
Brandon TH, Tiffany ST, Obremski KM, Baker TB. Postcessation cigarette use: the process of relapse. Addict Behav 1990; 15: 105-14. [CrossRef]
Hawk LW Jr, Ashare RL, Lohnes SF, Schlienz NJ, Rhodes JD, Tiffany ST, et al. The effects of extended pre-quit varenicline treatment on smoking behavior and short-term abstinence: a randomized clinical trial. Clin Pharmacol Ther 2012; 91: 172-80. [CrossRef]
Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006; 296: 64-71. [CrossRef]
Piper ME, Smith SS, Schlam TR, Fiore MC, Jorenby DE, Fraser D, et al. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry 2009; 66: 1253-62. [CrossRef]
Koegelenberg CF, Noor F, Bateman ED, Van Zyl-Smit RN, Bruning A, O'Brien JA, et al. Efficacy of varenicline combined with nicotine repla- cement therapy vs. varenicline alone for smoking cessation: a rando- mized clinical trial. JAMA 2014; 312: 155-61. [CrossRef]
Ebbert JO, Hatsukami DK, Croghan IT, Schroeder DR, Allen SS, Hays JT, et al. Combination varenicline and bupropion SR for tobacco-depen- dence treatment in cigarette smokers: a randomized trial. JAMA 2014; 311: 155-63. [CrossRef]
Stapleton J, West R, Hajek P, Wheeler J, Vangeli E, Abdi Z, et al. Rando- mized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practi- ce. Addiction 2013; 108: 2193-201. [CrossRef]
Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropi- on and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 47-55. [CrossRef]
Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha- 4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 56-63. [CrossRef]
Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano N, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006; 166: 1561-8. [CrossRef]
Stead LF, Lancaster T. Combined pharmacotherapy and behavioral in- terventions for smoking cessation. Cochrane Database Syst Rev 2012; 10:CD008286.
Suls JM, Luger TM, Curry SJ, Mermelstein RJ, Sporer AK, An LC. Efficacy of smoking-cessation interventions for young adults: a meta-analysis. Am J Prev Med 2012; 42: 655-62. [CrossRef]